Table 1.
Features of the included studies
| No | Author | Year | NCT | cancers | durgs | Pts | follow-up (months) | Effecacy | Safety |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Rodabe N. Amaria | 2018 | NCT02519322 | Melanoma | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 23 | 15.0 vs 15.6 | ORR, pCR, surgery rate, OS, PFS, RFS | 3–4 grade AEs |
| 2 | Boris Sepesia | 2022 | NCT03158129 | NSCLC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 44 | NA | surgery rate, R0 rate | all-cause mortality |
| 3 | Tina Casconea | 2021 | NCT03158129 | NSCLC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 44 | average 22.2 | ORR, MPR, pCR, OS, RFS | 3–4 grade AEs, completed therapy |
| 4 | Jonathan D Schoenfeldb | 2020 | NCT02919683 | OSCC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 29 | average 14.2 | ORR, MPR, pCR, OS, PFS | 3–4 grade AEs, completed therapy |
| 5 | Jonathan D Schoenfeldb | 2022 | NCT02919683 | OSCC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 29 | NA | NA | updated completed therapy, all-cause mortality |
| 6 | Renata Ferrarotto | 2020 | NCT03144778 | OPSCC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 28 | average 15.79 | ORR, MPR, pCR | 3–4 grade AEs |
| 7 | Ahmed Omar Kaseb | 2022 | NCT03222076 | HC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 27 | NA | ORR, pCR, PFS, surgery rate | 3–4 grade AEs, all-cause mortality |
| 8 | A. Leary | 2021 | NCT03249142 | OC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 66 | NA | MPR, surgery rate, R0 rate | 3–4 grade AEs, completed therapy |
| 9 | Hye Ryun Kim | 2021 | NCT03737968 | HNSCC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 36 | average 4.3 | ORR | NA |
| 10 | Hyun-Sung Lee | 2023 | NCT02592551 | MPM | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 20 | average 34.1 | MPR、AEs | NA |
Abbreviation: No. Number, Pts Participants, NSCLC Non-small cell cancer, OSCC Oral squamous cell carcinoma, OPSCC Oropharyngeal squamous cell carcinoma, HC Hepatic cancer, OC Ovarian cancer, HNSCC Head and neck squamous cell carcinoma, MPM Malignant pleural mesothelioma, NA Not applicable, ORR Overall response rate, MPR Main pathological response, pCR Pathological complete response, R0 Radical resection, OS Overall survival, PFS Progression-free survival, RFS Recurrence-free survival, AEs Adverse event rate
aAssessed the same clinical trial (NCT03158129) with different outcomes
bAssessed the same clinical trial (NCT02919683) with different outcomes